Fang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fang Liu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Avery D. Posey
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
24 shared publications - Emma E. Furth
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
23 shared publications - Shawna K. Brookens
University of Pennsylvania 1 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine Philadelphia, Pennsylvania
23 shared publications - Hyeon-Gyu S. Lewis
University of Pennsylvania 3 Philadelphia, Pennsylvania
14 shared publications - John T. Keane
UNIVERSITY OF PENNSYLVANIA 2
14 shared publications - Amal Ahmed
Meharry Medical College School of Medicine Nashville Tennessee USA
13 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
The Tn antigen, a truncated O-glycan, is frequently elevated in pancreatic ductal adenocarcinoma (PDAC). Multiple therapeutic approaches targeting Tn have been developed, but they have not demonstrated clear efficacy signals in early-phase clinical studies. Improving Tn-targeted strategies in PDAC will require both overcoming the immunosuppressive tumor microenvironment and defining pathways by which truncated O-glycans promote growth and immune evasion. In this study, we show that Tn reshapes the tumor immune landscape of PDAC. Expression of Tn antigen on PDAC cells enhanced proliferation in vitro and tumor growth in vivo. Tn expression remodeled the immune microenvironment, skewing tumor-associated macrophages toward M2-like phenotypes, reducing cross-presenting dendritic cells, and expanding myeloid-derived suppressor cells (MDSC). Single-cell RNA sequencing confirmed the expansion of MDSCs and downregulation of antigen processing and presentation in the immune cell infiltrate of Tn+ tumors. Tumor-intrinsic transcriptomic analyses revealed the activation of TNFα/NF-κB signaling and induction of IL34, a cytokine linked to monocyte survival and differentiation in Tn antigen–expressing tumors. Additionally, high Tn expression in both organoids derived from patients with pancreatic cancer and in PDAC mouse models was associated with increased IL34 expression. The genetic deletion of Il34 in PDAC cells attenuated Tn-driven tumorigenesis and reduced MDSC infiltration, whereas recombinant IL34 promoted myeloid cell differentiation and proliferation in vitro. Together, these findings establish a glyco–immune–cytokine axis in which truncated O-glycans contribute to IL34-mediated immunosuppression, providing mechanistic insights and potential therapeutic targets in PDAC. Significance:Altered glycosylation stimulates TNF-α/NF-κB signaling and induces IL-34-mediated accumulation of suppressive myeloid cells in pancreatic cancer, providing a myeloid-mediated mechanism of immunosuppression that could guide the development of therapies targeting glycosylation.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
The Tn antigen, a truncated O-glycan, is frequently elevated in pancreatic ductal adenocarcinoma (PDAC). Multiple therapeutic approaches targeting Tn have been developed, but they have not demonstrated clear efficacy signals in early-phase clinical studies. Improving Tn-targeted strategies in PDAC will require both overcoming the immunosuppressive tumor microenvironment and defining pathways by which truncated O-glycans promote growth and immune evasion. In this study, we show that Tn reshapes the tumor immune landscape of PDAC. Expression of Tn antigen on PDAC cells enhanced proliferation in vitro and tumor growth in vivo. Tn expression remodeled the immune microenvironment, skewing tumor-associated macrophages toward M2-like phenotypes, reducing cross-presenting dendritic cells, and expanding myeloid-derived suppressor cells (MDSC). Single-cell RNA sequencing confirmed the expansion of MDSCs and downregulation of antigen processing and presentation in the immune cell infiltrate of Tn+ tumors. Tumor-intrinsic transcriptomic analyses revealed the activation of TNFα/NF-κB signaling and induction of IL34, a cytokine linked to monocyte survival and differentiation in Tn antigen–expressing tumors. Additionally, high Tn expression in both organoids derived from patients with pancreatic cancer and in PDAC mouse models was associated with increased IL34 expression. The genetic deletion of Il34 in PDAC cells attenuated Tn-driven tumorigenesis and reduced MDSC infiltration, whereas recombinant IL34 promoted myeloid cell differentiation and proliferation in vitro. Together, these findings establish a glyco–immune–cytokine axis in which truncated O-glycans contribute to IL34-mediated immunosuppression, providing mechanistic insights and potential therapeutic targets in PDAC. Significance:Altered glycosylation stimulates TNF-α/NF-κB signaling and induces IL-34-mediated accumulation of suppressive myeloid cells in pancreatic cancer, providing a myeloid-mediated mechanism of immunosuppression that could guide the development of therapies targeting glycosylation.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Knockout of C1galt1c1 leads to altered proliferation in murine pancreatic adenocarcinoma clone 6499c4.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Knockout of C1galt1c1 leads to altered proliferation in murine pancreatic adenocarcinoma clone 6499c4.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Tn antigen expression on T cell-low mPDAC cell line alters composition of immune infiltrating cells.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Tn antigen expression on T cell-low mPDAC cell line alters composition of immune infiltrating cells.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Tn antigen expression on T cell-high mPDAC cell line alters immune composition.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Tn antigen expression on T cell-high mPDAC cell line alters immune composition.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Tn-Mgl2 interaction is dispensable for the tumorgenicity of Tn antigen expressing tumors.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Tn-Mgl2 interaction is dispensable for the tumorgenicity of Tn antigen expressing tumors.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Loss of Cosmc is associated with TNFα-NFκB pathway activation and IL-34 upregulation.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Loss of Cosmc is associated with TNFα-NFκB pathway activation and IL-34 upregulation.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
IL-34 receptors are expressed across the myeloid lineage and loss of IL-34 leads to enhanced M-CSF production in a Tn+ mPDAC clone.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
IL-34 receptors are expressed across the myeloid lineage and loss of IL-34 leads to enhanced M-CSF production in a Tn+ mPDAC clone.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Upregulated genes in isogenic C1galt1c1 KO mPDAC cell lines.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Upregulated genes in isogenic C1galt1c1 KO mPDAC cell lines.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Genes downregulated in isogenic C1galt1c1 KO mPDAC cell lines.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Aberrant O-Glycosylation Induces IL34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression
Genes downregulated in isogenic C1galt1c1 KO mPDAC cell lines.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Tumors remodel the extracellular matrix (ECM) and glycosylation, yielding epitopes with restricted or limited detectability in normal adult tissues. In this study, we evaluated the O-glycosylated type III connecting segment domain of fibronectin (Tn-FN) as a chimeric antigen receptor (CAR) T-cell target. FDC6-BBζ CAR T cells recognizing Tn-FN were benchmarked against extra domain B-FN–targeted L19-BBζ and Tn-MUC1–targeted 5E5-BBζ. FDC6-BBζ mediated robust, antigen-dependent activation and cytotoxicity, outperforming L19-BBζ and matching 5E5-BBζ in vitro and in NOD/SCID gamma xenografts of prostate cancer. FDC6-BBζ and 5E5-BBζ CAR T cells achieved durable tumor control with increased intratumoral CD3+ infiltration and reduced tumor–collagen overlap. Cytotoxicity required an intact tumor IFNγ receptor 1 (IFNγR1); L19-BBζ further depended on Fas, whereas FDC6-BBζ and 5E5-BBζ were less Fas-dependent. Tumoral Toll-like receptor (TLR) 2/6 or TLR4 agonism restored FDC6-BBζ killing of IFNγR1-deficient targets and induced broad inflammatory and stress–response programs. Pharmacologic perturbation implicated caspase-dependent mechanisms and a contribution from inflammasome-linked signaling, whereas ferroptosis blockade did not abrogate restored killing. These findings establish Tn-FN as a glycoform-restricted, ECM-derived CAR target and show that innate agonists can reprogram tumor state to overcome resistance from impaired IFNγ signaling.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Tumors remodel the extracellular matrix (ECM) and glycosylation, yielding epitopes with restricted or limited detectability in normal adult tissues. In this study, we evaluated the O-glycosylated type III connecting segment domain of fibronectin (Tn-FN) as a chimeric antigen receptor (CAR) T-cell target. FDC6-BBζ CAR T cells recognizing Tn-FN were benchmarked against extra domain B-FN–targeted L19-BBζ and Tn-MUC1–targeted 5E5-BBζ. FDC6-BBζ mediated robust, antigen-dependent activation and cytotoxicity, outperforming L19-BBζ and matching 5E5-BBζ in vitro and in NOD/SCID gamma xenografts of prostate cancer. FDC6-BBζ and 5E5-BBζ CAR T cells achieved durable tumor control with increased intratumoral CD3+ infiltration and reduced tumor–collagen overlap. Cytotoxicity required an intact tumor IFNγ receptor 1 (IFNγR1); L19-BBζ further depended on Fas, whereas FDC6-BBζ and 5E5-BBζ were less Fas-dependent. Tumoral Toll-like receptor (TLR) 2/6 or TLR4 agonism restored FDC6-BBζ killing of IFNγR1-deficient targets and induced broad inflammatory and stress–response programs. Pharmacologic perturbation implicated caspase-dependent mechanisms and a contribution from inflammasome-linked signaling, whereas ferroptosis blockade did not abrogate restored killing. These findings establish Tn-FN as a glycoform-restricted, ECM-derived CAR target and show that innate agonists can reprogram tumor state to overcome resistance from impaired IFNγ signaling.